The axis that involves the programmed death receptor-1 (PD-1) and its ligands (PD-L1 and PD-L2) has been consolidated as a new foundational component of therapeutic regimens across multiple tumor types in isolated use or in combination with other therapies [2]. The gene discussed is CD274; the disease is neoplasm.